title: The impact of neocyte transfusion in the management of thalassaemia.
abstract: Transfusional iron overload leading to cardiopathy and other severe complications continues to be a major problem in chronically transfused homozygous beta-thalassaemia patients. It is well known that young red cells (neocytes) survive longer after transfusion and therefore may contribute to the extension of the intervals between transfusions. We evaluated the impact of neocytes in the total annual blood requirements and consequently the transfusional iron load in 18 thalassaemia patients. A two-period study comparing transfusions of standard red cells versus neocytes in the same group of patients was performed. Neocytes were harvested by density separation using the Neocel System. The method of preparation was simple with relatively low costs and required no special equipment. There was a significant difference (p < 0.005) in PK and MCV values of the neocyte and older red cell (gerocyte) fractions indicating that a good separation of the two populations was achieved. All patients had a reduction in blood requirements during the neocyte period. The total annually transfused red blood cells and concomitant iron blood load were significantly reduced (p < 0.001) by 20.2 +/- 9.1%. However, the response was variable. Seven of the 18 patients had a large reduction in blood consumption (24.8-34.8%), 9 others ranged between 10.7 and 21.6%, and in 2 the reduction was less than 10%. This reduction in blood requirements and in the transfused iron may change the chelation index resulting in more efficient iron chelation therapy and perhaps reduce the cost of the haemochromatosis therapy on a long-term basis. We conclude that the use of neocyte therapy using this system can benefit the majority of chronically transfused patients by reducing transfusional iron overload and related complications and may lead to a much better quality of life.
authors.affiliation: Blood Transfusion Center, Aghia Sophia Paediatric Hospital, Athens, Greece.
authors.forename: T
authors.initials: T
authors.lastname: Spanos
authors.forename: V
authors.initials: V
authors.lastname: Ladis
authors.forename: F
authors.initials: F
authors.lastname: Palamidou
authors.forename: I
authors.initials: I
authors.lastname: Papassotiriou
authors.forename: A
authors.initials: A
authors.lastname: Banagi
authors.forename: E
authors.initials: E
authors.lastname: Premetis
authors.forename: C
authors.initials: C
authors.lastname: Kattamis
mesh_terms: D000293:Adolescent; D002469:Cell Separation / Q000191:economics; D002499:Centrifugation, Density Gradient; D015913:Chelation Therapy / Q000191:economics; D002648:Child; D003131:Combined Modality Therapy; D018592:Cross-Over Studies; D003676:Deferoxamine / Q000627:therapeutic use; D004905:Erythrocyte Aging; D017707:Erythrocyte Transfusion / Q000009:adverse effects / Q000191:economics / Q000706:statistics & numerical data; D005260:Female; D006801:Humans; D007501:Iron / Q000652:urine; D019190:Iron Overload / Q000188:drug therapy / Q000517:prevention & control*; D008297:Male; D011788:Quality of Life; D017262:Siderophores / Q000627:therapeutic use; D013156:Splenectomy; D017086:beta-Thalassemia / Q000601:surgery / Q000628:therapy*
chemical_list: D017262:Siderophores; D007501:Iron; D003676:Deferoxamine